The first IL-17A antagonist now approved for adult patients across the spectrum of axSpA (nr-axSpA, AS)  

Rheumatology Dosing1

DOSING FOR AS AND PsA

Convenient 1-day starting dose with a once-monthly* dosing schedule

Taltz dosing for rheumatology

*Every 4 weeks.

Starting dose of two 80 mg injections, followed by one 80 mg injection every 4 weeks thereafter.

The dosing regimen is the same for adult patients with AS and for adult patients with PsA without coexistent moderate to severe PsO.

For patients with PsA and coexistent moderate to severe PsO

After the starting dose of two 80 mg injections, 1 injection every 2 weeks for 3 months (12 weeks), then once a month* thereafter.

If patients forget to take their Taltz dose, instruct them to inject a dose as soon as they remember; then, to take their next dose at the regularly scheduled time.

Taltz is intended for use under the guidance and supervision of a physician. Patients may self-inject after training in subcutaneous injection technique. Evaluate patients for tuberculosis prior to initiating treatment with Taltz. For additional administration information, refer to the Instructions for Use included with the device.

DOSING FOR nr-axSpA

Convenient once-monthly* dosing schedule

Taltz dosing for rheumatology

*Every 4 weeks.

Starting dose of one 80 mg injection, followed by one 80 mg injection every 4 weeks thereafter.

Devices



Taltz has 2 device options, offering you the flexibility to choose the one that best suits your patients1,6

Devices designed with patients in mind

Dosing devices

At first use, over 94% of adult patients with moderate to severe plaque psoriasis agreed the Taltz autoinjector was “easy to use” and were confident in their ability to use it.

Please see Instructions for Use included with the device.

Device study trial design


References: 1. Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020. 2. Martin DA, Towne JE, Kricorian G, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013:133:17-26. 3. Kirkham BW, Kavanaugh A, Reich K. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology. 2013;141:133-142. 4. Paul C. Ixekizumab or secukinumab in psoriasis: what difference does it make? Br J Dermatol. 2018;178:1003-1005. 5. Taltz [instructions for use]. Indianapolis, IN: Eli Lilly and Company; 2018. 6. Callis Duffin K, Bukhalo M, Bobonich MA, et al. Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience. Med Devices (Auckl). 2016;9:361-369.

Indications and Important Safety Information
Indications

Taltz is indicated for adults with active psoriatic arthritis (PsA), for adults with active ankylosing spondylitis (AS), and for adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation. Taltz is also indicated for patients aged 6 years or older with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.

Important Safety Information
CONTRAINDICATIONS
Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

WARNINGS AND PRECAUTIONS
Infections
Taltz may increase the risk of infection. In clinical trials of adult patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.

Hypersensitivity
Serious hypersensitivity reactions, including angioedema and urticaria (each ≤0.1%), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.

Inflammatory Bowel Disease
Patients treated with Taltz may be at an increased risk of inflammatory bowel disease. In clinical trials, Crohn’s disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz group than the placebo group. During Taltz treatment, monitor patients for onset or exacerbations of inflammatory bowel disease and if IBD occurs, discontinue Taltz and initiate appropriate medical management.

Immunizations
Prior to initiating therapy with Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.

ADVERSE REACTIONS
Most common adverse reactions (≥1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. Overall, the safety profiles observed in adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis were consistent with the safety profile in adult patients with plaque psoriasis, with the exception of influenza and conjunctivitis in psoriatic arthritis and conjunctivitis, influenza, and urticaria in pediatric psoriasis.

Please click to access the Prescribing Information and Medication Guide. Please see Instructions for Use included with the device.
IX HCP ISI 07MAY2020